SLC7A1 Overexpression Is Involved in Energy Metabolism Reprogramming to Induce Tumor Progression in Epithelial Ovarian Cancer and Is Associated with Immune-Infiltrating Cells

• Published in: Journal of oncology Vol. 2022; pp. 1 - 21
• Main Authors: You, Shijing, Zhu, Xiaoying, Yang, Yao, Du, XiuZhen, Song, Kejuan, Zheng, Qingmei, Zeng, Pengjiao, Yao, Qin
• Format: Journal Article
• Language: English
• Published: New York Hindawi 12.09.2022; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Amino acids; Analysis; Antibodies; Arginine; Cancer therapies; Cell growth; Chemotherapy; Gene expression; Genetic aspects; Medical prognosis; Memory (Computers); Metabolism; Ovarian cancer; Penicillin; Phenylalanine; Prognosis; Proteins; China; Beijing China; United States > US; Japan
• ISSN: 1687-8450; 1687-8450; 1687-8469
• DOI: 10.1155/2022/5864826

Cationic amino acid transporters (SLC7A1/CAT1) are highly expressed in human ovarian cancer (OC) tissues. However, the specific biological functions and mechanisms involved remain unclear. We used bioinformatics analysis to explore SLC7A1 expression level, prognostic value, and tumor mutation burden (TMB) in ovarian cancer (OC) tissues. We performed in vitro experiments to identify the expression and biological function of SLC7A1 in epithelial ovarian cancer (EOC) tissues and cells. An amino acid autoanalyzer was used to detect the effect of SLC7A1 on amino acid metabolism in EOC cells. Finally, SLC7A1 in OC was evaluated for cell-to-cell signalling and immune infiltration using online databases. We found that increased SLC7A1 expression in EOC cells and tissues was associated with poorer survival outcomes (P<0.05) but not with tumor stage or grade of OC (P>0.05). SLC7A1 is involved in the transport of phenylalanine and arginine in EOC cells, and its knockdown reduced the proliferation and migration of EOC cells and the resistance of cells to cisplatin. Furthermore, the TIMER database indicated that SLC7A1 overexpression was significantly positively correlated with levels of CD4+ memory resting cells, CD8+ effector memory cells, M0 macrophages, and cancer-associated fibroblasts (CAFs) in OC (P<0.05) and significantly negatively correlated with CD4+ memory-activated cells (P<0.05). Cell immunofluorescence indicated that SLC7A1 overexpression may affect the distribution of immune-infiltrating lymphocytes in tumors by inhibiting the expression of CCL4. Therefore, we concluded that SLC7A1 is involved in the metabolic remodelling of amino acids in EOC to promote tumor development and cisplatin resistance and is related to the tumor-infiltrating immune microenvironment of OC. SLC7A1 is a biomarker for predicting EOC progression and cisplatin resistance and represents a promising target for EOC treatment.